Download PDF
Deutsche Heilpraktiker-Zeitschrift 2018; 13(06): 50-55
DOI: 10.1055/a-0657-2334
Praxis
Diagnostik und Therapie
© Karl F. Haug Verlag in Georg Thieme Verlag KG

Lösungen statt Leitlinien

Volker Schmiedel∗

Subject Editor:
Further Information

Publication History

Publication Date:
08 October 2018 (online)

    Permissions and Reprints

Summary

Überernährung, Alkohol, Übergewicht und Medikamente zählen zu den wichtigsten Risikofaktoren einer Fettleber, die rund ein Drittel der Bevölkerung betrifft. Die medizinischen Leitlinien bieten kaum therapeutische Hilfen, viele valide Studien liefern jedoch erfolgversprechende Therapieoptionen. Naturheilkundliche Mittel wie Omega-3-Fettsäuren, Mariendistel und Bitterstoffe führen in Verbindung mit einer Lebensstiländerung nahezu immer zu einer Rückbildung der Fettleber.

Keywords

Fettleber - Leitlinien - Überernährung - Übergewicht - Alkohol - Omega-3-Fettsäuren - Mariendistel - Leber - Fetteinlagerung - NASH - Leberzirrhose - Blutfett - FLI - fatty liver index - Elastografie - FibroScan® - Leberfibrose - AWMF - Triglyzeride - Fett - Fischöl - Lebertee - Artischocke
 

  • Verwendete Literatur

  • 1 Schmiedel V.. Hausputz für Leber & Galle.. 2012. Stuttgart; Trias:
    Google Scholar
  • 2 Schmiedel V.. Omega-3 – Öl des Lebens.. 2018. Lenzburg; Fona:
    Google Scholar
  • 3 Worm N.. Menschenstopfleber: Die verharmloste Volkskrankheit Fettleber.. 2016. Riva; München:
    Google Scholar
  • 4 Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F.. The burden of liver disease in Europe: a review of available epidemiological data.. J Hepatol 2013; 58: 593-608
    CrossrefPubMedGoogle Scholar
  • 5 Grundy SM, Cleeman JI, Daniels SR. et al Diagnosis and management of the metabolic syndrome: An American Heart Association / National Heart, Lung, and Blood Institute Scientific Statement.. Circulation 2005; 112: 2735-2752
    CrossrefPubMedGoogle Scholar
  • 6 Dunn W, Xu R, Schwimmer JB.. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease.. Hepatology 2008; 47: 1947-1954
    CrossrefPubMedGoogle Scholar
  • 7 Dunn W, Sanyal AJ, Brunt EM. et al Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with nonalcoholic fatty liver disease (NAFLD).. J Hepatol 2012; 57: 384-391
    CrossrefPubMedGoogle Scholar
  • 8 Sookoian S, Castano GO, Pirola CJ.. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43 175 individuals.. Gut 2014; 63: 530-532
    CrossrefPubMedGoogle Scholar
  • 9 Bedogni G. et al The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.. BMC Gastroenterol. 2006; 6: 33 Published online 2006 Nov 2. DOI: 10.1186/1471-230X-6–33
    CrossrefPubMedGoogle Scholar
  • 10 Roeb E. et al S2k Leitlinie Nicht-alkoholische Fettlebererkrankungen.. 2015. Giessen: https://www.awmf.org/uploads/tx_szleitlinien/021-025l_S25_NASH_Nicht_alkoholische_Fettlebererkrankung_2015-01.pdf
    Google Scholar
  • 11 Wah Kheong C, Nik Mustapha NR, Mahadeva S.. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.. Clin Gastroenterol Hepatol. 2017; 15 (12) 1940-1949.e8 DOI: 10.1016/j.cgh.2017.04.016
    CrossrefPubMedGoogle Scholar
  • 12 Sofi F, Giangrandi I, Cesari F. et al Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study.. Int J Food Sci Nutr 2010; 61: 792-802
    CrossrefPubMedGoogle Scholar
  • 13 de Castro GS, Calder PC.. Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids.. Clin Nutr. 2018; 37 (01) 37-55 DOI: 10.1016/j.clnu.2017.01.006
    CrossrefPubMedGoogle Scholar
  • 14 Lu W. et al Effects of Omega-3 Fatty Acid in Nonalcoholic Fatty Liver Disease: A Meta-Analysis.. Gastroenterol Res Pract. 2016; 2016 (01) 459-790 DOI: 10.1155/2016/1459790
    Google Scholar
  • 15 Gao M. et al Fish consumption and n-3 polyunsaturated fatty acids, and risk of hepatocellular carcinoma: systematic review and meta-analysis.. Cancer Causes Control. 2015; 26 (03) 367-76 DOI: 10.1007/s10552-014–0512–1
    CrossrefPubMedGoogle Scholar
  • 16 Hodson L. et al Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study.. Eur J Clin Nutr. 2017; 71 (08) 973-979 Aug; DOI: 10.1038/ejcn.2017.9
    CrossrefPubMedGoogle Scholar
  • 17 Boyraz M. et al Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease.. J Clin Res Pediatr Endocrinol 2015; 7 (02) 121-7 DOI: 10.4274/jcrpe. 1749
    CrossrefPubMedGoogle Scholar
  • 18 Dasarathy S. et al Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis.. J Clin Gastroenterol. 2015; 49 (02) 137-44 DOI: 10.1097/MCG.0000000000000099
    CrossrefPubMedGoogle Scholar
  • 19 Ryan MC. et al The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease.. J Hepatol. 2013; 59 (01) 138-43 DOI: 10.1016/j.jhep.2013.02.012
    CrossrefPubMedGoogle Scholar
  • 20 Cao et al. Hydroxytyrosol prevents diet-induced metabolic syndrome and attenuates mitochondrial abnormalities in obese mice. Free Radic Biol Med. 2014; 67: 396-407, DOI: 10.1016/j.freeradbiomed.2013.11.029